If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
129.00    1.00 (0.78%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £537.17m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

29 Jul 2025 07:00

RNS Number : 8873S
James Halstead PLC
29 July 2025
 

 

29 July 2025

 

 

JAMES HALSTEAD PLC (the "Company")

 

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2025.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring but has experienced headwinds against sales of luxury vinyl tile (LVT) principally in Europe, the Company has however successfully managed to grow its market share in the UK. Profit before tax is in line with expectations.

 

Sales in the UK, our largest market, have improved compared to the prior financial year. Having reported that in the prior financial year there was a 5% decline versus the comparative, it is pleasing to note that our performance this year has seen this decline more than fully reverse. This is despite a degree of de-stocking by some customers, particularly those with exposure to the UK domestic carpet market.

 

Sales volumes of LVT have increased, albeit modestly, in a market segment that has seen a large decline in demand. Sales of Polyflor branded LVT products have held up due to their quality and value together with our widely accepted reputation for sustainability and environmental excellence; factors that have helped increase our market share. LVT and sheet vinyl continue to displace carpet sales in the UK market.

 

Notwithstanding this backdrop and solid UK performance, our internal expectations for the UK were higher. An anticipated uplift in demand in the education, healthcare and the prison sectors has not, yet, materialised though sales into the aged care and affordable housing sectors are performing satisfactorily.

 

In Europe, particularly in France and Holland, there has been muted activity in consumer spending which has affected refurbishment demand and new store openings in the retail sector. This has impacted LVT sales and volume declines were further compounded by increased focus of government budgets towards national security, diverting spending away from such areas as construction and social housing.

 

The products we sell are still regarded as market leading but the year has required reacting to a lower level of sales by tight cost control. In this regard, the simple model of holding stock within our distribution chain to supply demand is tried and tested around the globe.

 

In our Rest of World markets, sales have generally been more positive with very good growth, especially in the Americas, the Middle East and Mediterranean regions. Additionally, South Asia has seen the growth of recent years continue and is 38% ahead of the comparative of last year.

 

Notwithstanding the slower sales, the Group's focus on manufacturing efficiency and tight cost control of overheads have protected margins.

 

Operationally, there has been disruption to global trade routes and shipping movements with the uncertainty of tariffs on sales into the USA which has affected deliveries into many markets. However, these uncertainties have been positive regarding the sale of our UK manufactured goods into the USA, as customers seek alternative suppliers to replace products imported from countries where much higher tariffs have been imposed and with continuing uncertainly. This increased demand is despite an additional 10% duty cost to importers of our UK products.

 

In summary, the Company anticipates that sales will be marginally below the 2024 comparative with profit slightly below last year's record levels; although remaining within the range of market expectations. Cash generation alongside reserves continue to underpin an ungeared balance sheet, which remains strong.

 

The Board is confident that the prospects remain solid despite the recent external challenges and side winds.

 

The Company expects to announce its results for the year ended 30 June 2025 towards the end of September 2025.

 

 

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Executive Chairman

Gordon Oliver, Chief Executive

David Drillingcourt, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQCBKDPOB
Date   Source Headline
2nd Jul 20129:00 amRNSBlocklisting Interim Review
6th Jun 20124:40 pmRNSSecond Price Monitoring Extn
6th Jun 20124:35 pmRNSPrice Monitoring Extension
1st Jun 20127:00 amRNSTotal Voting Rights
25th May 20122:00 pmRNSDirector/PDMR Shareholding
1st May 20127:00 amRNSTotal Voting Rights
2nd Apr 20123:45 pmRNSDirector/PDMR Shareholding
29th Mar 20127:00 amRNSInterim Results
12th Mar 20124:35 pmRNSPrice Monitoring Extension
1st Mar 20127:00 amRNSTotal Voting Rights
30th Jan 20127:00 amRNSPre-Close Trading Statement
11th Jan 20127:00 amRNSAppointment of Broker
4th Jan 20127:00 amRNSAppointment of non-executive director
3rd Jan 20127:00 amRNSBlocklisting Interim Review
3rd Jan 20127:00 amRNSTotal Voting Rights
6th Dec 20111:00 pmRNSDirector's shareholding
5th Dec 20114:45 pmRNSChange in shareholdings
2nd Dec 20117:00 amRNSAGM Statement
30th Nov 201110:50 amRNSResult of Tender Offer
14th Nov 20117:00 amRNSTender Offer and Trading Update
1st Nov 20117:00 amRNSTotal Voting Rights
28th Oct 20112:00 pmRNSAnnual Financial Report
11th Oct 201111:00 amRNSChange in Director's Holding
3rd Oct 20117:00 amRNSPreliminary Results
6th Sep 20117:00 amRNSNotice of Results
15th Aug 20117:00 amRNSTotal Voting Rights
26th Jul 20117:00 amRNSPre-close Trading Statement
6th Jul 20118:45 amRNSDirector/PDMR Shareholding
1st Jul 20117:00 amRNSBlocklisting Interim Review
3rd May 20117:00 amRNSTotal Voting Rights
15th Apr 20112:40 pmRNSDirector/PDMR Shareholding
1st Apr 20117:00 amRNSTotal Voting Rights
31st Mar 20117:00 amRNSInterim Results
31st Jan 20112:00 pmRNSHolding(s) in Company
31st Jan 20117:00 amRNSPre-close Trading Statement
13th Jan 20113:30 pmRNSIssue of Equity and Total Voting Rights
12th Jan 20119:30 amRNSBonus Issue
4th Jan 20119:45 amRNSTotal Voting Rights
4th Jan 20119:10 amRNSBlocklisting Interim Review
21st Dec 20103:45 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSAnnual General Meeting
1st Nov 20107:00 amRNSTotal Voting Rights
25th Oct 20109:15 amRNSAnnual Report and Accounts
25th Oct 20109:15 amRNSAnnual Report and Accounts
30th Sep 20107:00 amRNSPreliminary Results
23rd Jul 20107:00 amRNSPre-Close Trading Update
1st Jul 20107:00 amRNSBlocklisting Interim Review
6th Apr 201012:00 pmRNSTotal Voting Rights
31st Mar 20104:17 pmRNSDirector/PDMR Shareholding
31st Mar 20107:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.